EZH2 and Miyoshi myopathy: Similarly, EZH2 inhibition was shown to be effective in MM cell lines, and clinical trials are currently exploring its potential in MM patients (Tremblay-LeMay et al., 2018; Yap et al., 2019), although not in a targeted segment.